Syneron Bio closed a $150 million Series B to support its macrocyclic peptide development platform, after earlier funding and a multibillion-dollar biobucks deal with AstraZeneca. The round follows the company’s nearly $100 million funding last year and is positioned as a continued bet on peptide discovery and optimization. The company said the Series B will fund platform development and program execution, reinforcing competition in peptide-based drug discovery at a time when large pharma partnerships are reshaping how peptide leads are generated. With the financing, Syneron increases its runway for discovery-to-development work, including improving the processes behind macrocyclic peptide creation and candidate selection.